Biomedical Journal

Papers
(The H4-Index of Biomedical Journal is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID-19: The first documented coronavirus pandemic in history479
Artificial intelligence approach fighting COVID-19 with repurposing drugs156
Comprehensive review of coronavirus disease 2019 (COVID-19)97
DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects87
Innate immunity drives pathogenesis of rheumatoid arthritis86
Understanding the role of neutrophils in acute respiratory distress syndrome83
Brain-derived neurotrophic factor and mental disorders77
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines70
Machine learning techniques for sequence-based prediction of viral–host interactions between SARS-CoV-2 and human proteins69
Is there an association between oral health and severity of COVID-19 complications?61
Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-1961
Human adenovirus infections in pediatric population - An update on clinico–pathologic correlation60
The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness52
Repurposing old drugs as antiviral agents for coronaviruses49
G6PD: A hub for metabolic reprogramming and redox signaling in cancer41
Pediatric abusive head trauma40
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment38
Development of multi-epitope peptide-based vaccines against SARS-CoV-236
Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation35
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention35
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions33
Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor33
LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570–3p28
Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-228
Exposure to PM2.5 and PM10 and COVID-19 infection rates and mortality: A one-year observational study in Poland28
RASopathies: From germline mutations to somatic and multigenic diseases27
SARS-CoV-2 variants – Evolution, spike protein, and vaccines26
0.042336940765381